DK0749424T3 - Naphthalenderivater som prostaglandin-I2-agonister - Google Patents
Naphthalenderivater som prostaglandin-I2-agonisterInfo
- Publication number
- DK0749424T3 DK0749424T3 DK95910763T DK95910763T DK0749424T3 DK 0749424 T3 DK0749424 T3 DK 0749424T3 DK 95910763 T DK95910763 T DK 95910763T DK 95910763 T DK95910763 T DK 95910763T DK 0749424 T3 DK0749424 T3 DK 0749424T3
- Authority
- DK
- Denmark
- Prior art keywords
- prostaglandin
- agonists
- hydroxy
- naphthalene derivatives
- hydrogen
- Prior art date
Links
- 239000000556 agonist Substances 0.000 title 1
- KAQKFAOMNZTLHT-VVUHWYTRSA-N epoprostenol Chemical compound O1C(=CCCCC(O)=O)C[C@@H]2[C@@H](/C=C/[C@@H](O)CCCCC)[C@H](O)C[C@@H]21 KAQKFAOMNZTLHT-VVUHWYTRSA-N 0.000 title 1
- 229960001123 epoprostenol Drugs 0.000 title 1
- 150000002790 naphthalenes Chemical class 0.000 title 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 4
- 229910052739 hydrogen Inorganic materials 0.000 abstract 3
- 239000001257 hydrogen Substances 0.000 abstract 3
- 125000002947 alkylene group Chemical group 0.000 abstract 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 2
- 150000002431 hydrogen Chemical group 0.000 abstract 2
- 125000000217 alkyl group Chemical group 0.000 abstract 1
- 125000003118 aryl group Chemical group 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 229910052736 halogen Chemical group 0.000 abstract 1
- 150000002367 halogens Chemical group 0.000 abstract 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/63—One oxygen atom
- C07D213/64—One oxygen atom attached in position 2 or 6
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
- C07C271/06—Esters of carbamic acids
- C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
- C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C271/12—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
- C07C271/06—Esters of carbamic acids
- C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
- C07C271/26—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atom of at least one of the carbamate groups bound to a carbon atom of a six-membered aromatic ring
- C07C271/28—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atom of at least one of the carbamate groups bound to a carbon atom of a six-membered aromatic ring to a carbon atom of a non-condensed six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C281/00—Derivatives of carbonic acid containing functional groups covered by groups C07C269/00 - C07C279/00 in which at least one nitrogen atom of these functional groups is further bound to another nitrogen atom not being part of a nitro or nitroso group
- C07C281/02—Compounds containing any of the groups, e.g. carbazates
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
- C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D237/14—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D303/00—Compounds containing three-membered rings having one oxygen atom as the only ring hetero atom
- C07D303/02—Compounds containing oxirane rings
- C07D303/12—Compounds containing oxirane rings with hydrocarbon radicals, substituted by singly or doubly bound oxygen atoms
- C07D303/16—Compounds containing oxirane rings with hydrocarbon radicals, substituted by singly or doubly bound oxygen atoms by esterified hydroxyl radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2602/00—Systems containing two condensed rings
- C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
- C07C2602/04—One of the condensed rings being a six-membered aromatic ring
- C07C2602/10—One of the condensed rings being a six-membered aromatic ring the other ring being six-membered, e.g. tetraline
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Epoxy Compounds (AREA)
- Pyridine Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB9404734A GB9404734D0 (en) | 1994-03-10 | 1994-03-10 | Heterocyclic compounds |
| GB9407036A GB9407036D0 (en) | 1994-04-08 | 1994-04-08 | Naphthalene derivatives |
| PCT/JP1995/000373 WO1995024393A1 (en) | 1994-03-10 | 1995-03-08 | Naphthalene derivatives as prostaglandin i2 agonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK0749424T3 true DK0749424T3 (da) | 2001-11-26 |
Family
ID=26304472
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK95910763T DK0749424T3 (da) | 1994-03-10 | 1995-03-08 | Naphthalenderivater som prostaglandin-I2-agonister |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US5763489A (enExample) |
| EP (1) | EP0749424B1 (enExample) |
| JP (1) | JP3245864B2 (enExample) |
| KR (1) | KR100383305B1 (enExample) |
| CN (1) | CN1057522C (enExample) |
| AT (1) | ATE205479T1 (enExample) |
| AU (1) | AU688871B2 (enExample) |
| CA (1) | CA2185104A1 (enExample) |
| DE (1) | DE69522676T2 (enExample) |
| DK (1) | DK0749424T3 (enExample) |
| ES (1) | ES2160156T3 (enExample) |
| GR (1) | GR3037080T3 (enExample) |
| HU (1) | HU224822B1 (enExample) |
| PT (1) | PT749424E (enExample) |
| RU (1) | RU2155188C2 (enExample) |
| TW (1) | TW282456B (enExample) |
| WO (1) | WO1995024393A1 (enExample) |
Families Citing this family (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK0736018T3 (da) * | 1993-12-20 | 2000-09-18 | Fujisawa Pharmaceutical Co | 4,5-Diaryloxazolderivater |
| TW401408B (en) | 1995-07-21 | 2000-08-11 | Fujisawa Pharmaceutical Co | Heterocyclic compounds having prostaglandin I2 agonism |
| DE19537548A1 (de) * | 1995-10-09 | 1997-04-10 | Merck Patent Gmbh | Endothelin-Rezeptor-Antagonisten |
| DE19604191A1 (de) * | 1996-02-06 | 1997-08-07 | Hoechst Schering Agrevo Gmbh | 2,4-Diamino-1,3,5-triazine, Verfahren zu deren Herstellung und deren Verwendung als Herbizide und Pflanzenwachstumsregulatoren |
| AUPO713297A0 (en) * | 1997-06-02 | 1997-06-26 | Fujisawa Pharmaceutical Co., Ltd. | Oxazole compound |
| GB9720270D0 (en) | 1997-09-25 | 1997-11-26 | Pharmagene Lab Limited | Medicaments for the treatment of migraine |
| AUPP003297A0 (en) | 1997-10-27 | 1997-11-20 | Fujisawa Pharmaceutical Co., Ltd. | 4,5-diaryloxazole compounds |
| AUPP029197A0 (en) * | 1997-11-10 | 1997-12-04 | Fujisawa Pharmaceutical Co., Ltd. | Benzocycloheptene derivatives |
| AUPP109097A0 (en) * | 1997-12-22 | 1998-01-22 | Fujisawa Pharmaceutical Co., Ltd. | Napthalene derivatives |
| US6335459B1 (en) | 1998-12-23 | 2002-01-01 | Syntex (U.S.A.) Llc | Aryl carboxylic acid and aryl tetrazole derivatives as IP receptor modulators |
| US20040127529A1 (en) * | 1999-06-21 | 2004-07-01 | Fujisawa Pharmaceutical Co., Ltd. | Remedies for skin ulcer |
| AU5249200A (en) * | 1999-06-21 | 2001-01-09 | Fujisawa Pharmaceutical Co., Ltd. | Remedies for skin ulcer |
| WO2002042243A1 (fr) * | 2000-11-21 | 2002-05-30 | Fujisawa Pharmaceutical Co., Ltd | Processus de preparation de derives de tetrahydronaphtalene |
| WO2002085412A1 (en) * | 2001-04-18 | 2002-10-31 | Fujisawa Pharmaceutical Co., Ltd. | Tissue fibrosis inhibitors |
| ES2636943T3 (es) | 2003-05-09 | 2017-10-10 | Toray Industries, Inc. | Beraprost y un inhibidor del sistema renina-angiotensina para usar en el tratamiento de enfermedades renales |
| AR059898A1 (es) | 2006-03-15 | 2008-05-07 | Janssen Pharmaceutica Nv | Derivados de 3-ciano-piridona 1,4-disustituida y su uso como moduladores alostericos de los receptores mglur2 |
| EP2094662B1 (en) | 2006-12-14 | 2012-04-11 | Astellas Pharma Inc. | Polycyclic acid compounds useful as crth2 antagonists and antiallergic agents |
| TW200900065A (en) | 2007-03-07 | 2009-01-01 | Janssen Pharmaceutica Nv | 3-cyano-4-(4-pyridinyloxy-phenyl)-pyridin-2-one derivatives |
| TW200845978A (en) | 2007-03-07 | 2008-12-01 | Janssen Pharmaceutica Nv | 3-cyano-4-(4-tetrahydropyran-phenyl)-pyridin-2-one derivatives |
| EA017648B1 (ru) | 2007-09-14 | 2013-02-28 | Орто-Макнейл-Янссен Фармасьютикалз, Инк. | 1',3'-двузамещенные-4-фенил-3,4,5,6-тетрагидро-2н,1'н-[1,4']бипириди-нил-2'-оны |
| US8895776B2 (en) | 2008-03-18 | 2014-11-25 | Arena Pharmaceuticals, Inc. | Modulators of the prostacyclin (PGI2) receptor useful for the treatment of disorders related thereto |
| JP5547194B2 (ja) | 2008-09-02 | 2014-07-09 | ジャンセン ファーマシューティカルズ， インコーポレイテッド． | 代謝型グルタミン酸受容体の調節因子としての３−アザビシクロ［３．１．０］ヘキシル誘導体 |
| JP5690277B2 (ja) | 2008-11-28 | 2015-03-25 | ジャンセン ファーマシューティカルズ， インコーポレイテッド． | 代謝型グルタミン酸受容体の調節因子としてのインドールおよびベンゾオキサジン誘導体 |
| MY153913A (en) | 2009-05-12 | 2015-04-15 | Janssen Pharmaceuticals Inc | 7-aryl-1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors |
| CN102439015B (zh) | 2009-05-12 | 2015-05-13 | 杨森制药有限公司 | 1,2,4-三唑并[4,3-a]吡啶衍生物和其作为mGluR2受体的正向变构调节剂的用途 |
| HRP20131122T1 (hr) | 2009-05-12 | 2013-12-20 | Janssen Pharmaceuticals, Inc. | Derivati 1,2,4-triazolo[4,3-a] piridina i njihova uporaba u lijeäśenju ili prevenciji neuroloških i psihijatrijskih poremeä†aja |
| JP5852664B2 (ja) | 2010-11-08 | 2016-02-03 | ジヤンセン・フアーマシユーチカルズ・インコーポレーテツド | １，２，４−トリアゾロ［４，３−ａ］ピリジン誘導体およびｍＧｌｕＲ２受容体のポジティブアロステリックモジュレーターとしてのそれらの使用 |
| ES2536433T3 (es) | 2010-11-08 | 2015-05-25 | Janssen Pharmaceuticals, Inc. | Derivados de 1,2,4-triazolo[4,3-a]piridina y su uso como moduladores alostéricos positivos de receptores mGluR2 |
| EP2661435B1 (en) | 2010-11-08 | 2015-08-19 | Janssen Pharmaceuticals, Inc. | 1,2,4-TRIAZOLO[4,3-a]PYRIDINE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS |
| JO3368B1 (ar) | 2013-06-04 | 2019-03-13 | Janssen Pharmaceutica Nv | مركبات 6، 7- ثاني هيدرو بيرازولو [5،1-a] بيرازين- 4 (5 يد)- اون واستخدامها بصفة منظمات تفارغية سلبية لمستقبلات ميجلور 2 |
| JO3367B1 (ar) | 2013-09-06 | 2019-03-13 | Janssen Pharmaceutica Nv | مركبات 2،1، 4- ثلاثي زولو [3،4-a] بيريدين واستخدامها بصفة منظمات تفارغية موجبة لمستقبلات ميجلور 2 |
| ME03518B (me) | 2014-01-21 | 2020-04-20 | Janssen Pharmaceutica Nv | Kombinacije koje obuhvataju pozitivne alosterične modulatore ili ortosterične agoniste metabotropnog glutamatergičnog receptora podtipa 2 i njihova primjena |
| PL3096790T3 (pl) | 2014-01-21 | 2020-01-31 | Janssen Pharmaceutica, N.V. | Kombinacje zawierające pozytywne modulatory allosteryczne lub agonistów ortosterycznych metabotropowego receptora glutaminergicznego podtypu 2 i ich zastosowanie |
| IL268997B2 (en) | 2017-03-01 | 2023-09-01 | Arena Pharm Inc | Preparations containing pgi2 receptor agonists and processes for their preparation |
| WO2023158634A1 (en) | 2022-02-15 | 2023-08-24 | United Therapeutics Corporation | Crystalline prostacyclin (ip) receptor agonist and uses thereof |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SU1366514A1 (ru) * | 1986-01-28 | 1988-01-15 | Днепропетровский химико-технологический институт им.Ф.Э.Дзержинского | Способ получени производных N-арил-5-ариламидо-4,6-диметилпиридона-2 |
| DE3837809A1 (de) * | 1988-11-08 | 1990-05-10 | Merck Patent Gmbh | Tetralinderivate |
| US5344836A (en) * | 1991-11-11 | 1994-09-06 | Ono Pharmaceutical Co., Ltd. | Fused benzeneoxyacetic acid derivatives |
-
1995
- 1995-03-08 CA CA002185104A patent/CA2185104A1/en not_active Abandoned
- 1995-03-08 AT AT95910763T patent/ATE205479T1/de not_active IP Right Cessation
- 1995-03-08 HU HU9602466A patent/HU224822B1/hu not_active IP Right Cessation
- 1995-03-08 CN CN95192846A patent/CN1057522C/zh not_active Expired - Fee Related
- 1995-03-08 JP JP52335695A patent/JP3245864B2/ja not_active Expired - Fee Related
- 1995-03-08 KR KR1019960704963A patent/KR100383305B1/ko not_active Expired - Fee Related
- 1995-03-08 ES ES95910763T patent/ES2160156T3/es not_active Expired - Lifetime
- 1995-03-08 WO PCT/JP1995/000373 patent/WO1995024393A1/en not_active Ceased
- 1995-03-08 PT PT95910763T patent/PT749424E/pt unknown
- 1995-03-08 TW TW084102192A patent/TW282456B/zh active
- 1995-03-08 DE DE69522676T patent/DE69522676T2/de not_active Expired - Fee Related
- 1995-03-08 DK DK95910763T patent/DK0749424T3/da active
- 1995-03-08 RU RU96120174/04A patent/RU2155188C2/ru not_active IP Right Cessation
- 1995-03-08 EP EP95910763A patent/EP0749424B1/en not_active Expired - Lifetime
- 1995-03-08 US US08/702,546 patent/US5763489A/en not_active Expired - Fee Related
- 1995-03-08 AU AU18618/95A patent/AU688871B2/en not_active Ceased
-
1998
- 1998-02-23 US US09/028,861 patent/US5863918A/en not_active Expired - Fee Related
-
2001
- 2001-10-31 GR GR20010401952T patent/GR3037080T3/el not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| HU224822B1 (en) | 2006-02-28 |
| HU9602466D0 (en) | 1996-11-28 |
| RU2155188C2 (ru) | 2000-08-27 |
| US5863918A (en) | 1999-01-26 |
| DE69522676T2 (de) | 2002-04-18 |
| TW282456B (enExample) | 1996-08-01 |
| WO1995024393A1 (en) | 1995-09-14 |
| EP0749424A1 (en) | 1996-12-27 |
| ATE205479T1 (de) | 2001-09-15 |
| CA2185104A1 (en) | 1995-09-14 |
| DE69522676D1 (de) | 2001-10-18 |
| JPH09509958A (ja) | 1997-10-07 |
| KR100383305B1 (ko) | 2003-11-01 |
| HUT75226A (en) | 1997-04-28 |
| ES2160156T3 (es) | 2001-11-01 |
| CN1057522C (zh) | 2000-10-18 |
| AU688871B2 (en) | 1998-03-19 |
| EP0749424B1 (en) | 2001-09-12 |
| PT749424E (pt) | 2002-03-28 |
| HK1013289A1 (en) | 1999-08-20 |
| US5763489A (en) | 1998-06-09 |
| JP3245864B2 (ja) | 2002-01-15 |
| GR3037080T3 (en) | 2002-01-31 |
| KR970701698A (ko) | 1997-04-12 |
| CN1147250A (zh) | 1997-04-09 |
| AU1861895A (en) | 1995-09-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| GR3037080T3 (en) | Naphthalene derivatives as prostaglandin i2 agonists | |
| ATE297203T1 (de) | Antithrombotische mitteln | |
| IL133627A0 (en) | Antithrombotic agents | |
| KR20050085991A (en) | Compounds exhibiting thrombopoietin receptor agonism | |
| TR199700844T1 (xx) | Pirazolil-Benzoil T�revleri. | |
| DK1177176T3 (da) | Triarylsyrederivater som PPAR-receptorligander | |
| ATE194335T1 (de) | 4,5-diaryloxazol-derivate | |
| TR200200579T2 (tr) | Amino-tirazolpiridin türevleri. | |
| DK0865281T3 (da) | Naphthylsubstituerede benzimidazolderivater som antikoagulerende midler | |
| ATE292634T1 (de) | Inhibitoren der alpha-l beta-2 vermittelten zelladhäsion | |
| IT1255802B (it) | Derivati imidazolici ad attivita' a ii antagonista | |
| TR200001452T2 (tr) | Bifenilamidin türevleri. | |
| ATE308540T1 (de) | Antithrombosemittel | |
| TR200001909T2 (tr) | Matris metaloprotez inhibitörleri. | |
| AR044175A1 (es) | Compuestos de cefemo | |
| ATE157369T1 (de) | 3'-azaridino-anthracyclin-derivate | |
| HRP20010885B1 (en) | Ethanesulfonyl-piperidine derivatives | |
| ATE200291T1 (de) | Cephemderivate | |
| TW333533B (en) | Novel indane-2-mercaptoacetylamide disulfide derivatives useful as inhibitors of enkephalinase | |
| NO20003138L (no) | Ny anvendelse av lokalanestetika mot vaskulære hodepiner | |
| MX9603617A (es) | Derivados de naftaleno. | |
| TW329388B (en) | Intraocular irrigating solution | |
| ES2132255T3 (es) | Nuevos compuestos de flavilio farmaceuticamente activos. | |
| TW358809B (en) | Phenylamidinothiophene compound and anti-inflammatory agent containing the same | |
| DE69528984D1 (de) | Hemmung der leukotrienbiosynthese mittels harnstoffderivaten |